Though the clinical significance of such fusions remains uncertain, precedents in other cancers—such as FGFR2 fusions showing therapeutic potential in cholangiocarcinoma patients treated with pemigatinib [24] and futibatinib [25]—suggest that FGFR alterations may play a significant role in targeted therapy and prognosis in lung squamous cell carcinoma, warranting further investigation. The gene discussed is FGFR2; the disease is cholangiocarcinoma.